Glenmark Pharmaceuticals ltd — Capital/Financing Update 2026

Mar 19, 2026

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

March 19, 2026

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®2 Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

Kindly find attached media release which is self- explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK VINAYAK KUBER Date: 2026.03.19 KUBER 08:23:06 +05'30' Harish Kuber Company Secretary & Compliance Officer Encl: as above

Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [595 x 132] intentionally omitted <==

Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg

Elmwood Park, New Jersey, March 19, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch[1] of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella®[2] Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

According to IQVIA[TM] sales data for the 12-month period ending January 2026, the Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market[2] achieved annual sales of approximately $102.9 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America

said, “We are excited to announce the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg, the authorized generic to Savella® Tablets. This launch further strengthens our commitment to bring to market quality and affordable alternatives for patients.”

1Glenmark’s Milnacipran Hydrochloride Tablets is only approved for the indication(s) listed in Glenmark’s approved label.

2All brand names and trademarks are the property of their respective owners.

3Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.

*IQVIA[TM] National Sales Perspectives: Retail & Non-Retail, January 2026

About Glenmark Pharmaceuticals Limited

‐ Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cuttingedge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and

==> picture [612 x 37] intentionally omitted <==

==> picture [595 x 132] intentionally omitted <==

oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.

For more information, please contact:

In the U.S.: Akhila Natarajan mediarelations@glenmarkpharma.com +91 98216 89525 Danielle Hagen, Nahigian Strategies danielle@nahigianstrategies.com 202-365-6112	In India: Akhila Natarajan mediarelations@glenmarkpharma.com +91 98216 89525 Adfactors PR glenmark@adfactorspr.com +91 88502 91322

==> picture [612 x 37] intentionally omitted <==